

## **REMARKS**

The present invention relates to regulatory T cells and methods of long-term, culture-expanding, activating and using same in immunotherapy and for the suppression of autoimmune responses, including GVHD.

### **In the Specification**

The specification has been amended herein to properly reflect the priority information of the present application. In particular, page 1 of the specification has been amended to recite that the present application claims priority to US Provisional Application No. 60/463,591, filed on April 17, 2003, and US Provisional Application No. 60/550,481, filed March 5, 2004.

The present Preliminary Amendment is filed with, as a separate paper, a Petition for Acceptance of Priority Claim Under 37 C.F.R. § 1.78(a)(6).

Summary

Applicants respectfully submit that the specification has merely been amended herein to correct the priority information of the present application. No new matter has been added by way of the present Preliminary Amendment.

Favorable examination of the claims is hereby requested.

Respectfully submitted,

BRUCE BLAZAR et al.

September 19, 2005  
(Date)

Evelyn H. McConathy  
Evelyn H. McConathy  
Registration No. 35,279  
DRINKER BIDDLE & REATH LLP  
One Logan Square  
18<sup>th</sup> and Cherry Streets  
Philadelphia, PA 19103-6996  
Tel: (215) 988.3361  
Fax: (215) 988.2757  
Attorney for Applicants

EHM/JDGB

Enclosures: Petition for Acceptance of Priority Claim Under 37 C.F.R. § 1.78(a)(6)